Antithrombotic Therapy for VTE Disease

ACCP VTE Therapy

ACCP GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/86135

Contents of this Issue

Navigation

Page 17 of 17

Grading System Strength of Recommendation Grade 1 = stronga Grade 2 = weakb a A = high Quality of Evidence B = moderate b Grade 2 suggests that individual patient values may lead to different choices. C = low Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Abbreviations ACCP, American College of Chest Physicians; CDT, catheter-directed thrombolysis; CrCl, creatinine clearance; CTPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; INR, international normalized ratio; IV, intravenous; IVC, inferior vena cava; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; PTS, postthrombotic (phlebitic) syndrome; RR, risk ratio; rt-PA, recombinant tissue plasminogen activator; subcut, subcutaneous; SBP, systolic blood pressure; SVT, superficial vein thrombosis; tPA, tissue plasminogen activator; UEDVT, upper-extremity DVT; UFH, unfractionated heparin; VKA, vitamin K antagonist; VTE, venous thromboembolism Source Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson M, Wells P, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines CHEST 2012; 141(2)(Suppl):e418S–e494S. Disclaimer This Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. VTE10122g 5740 Executive Drive Suite 218 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2012 All rights reserved

Articles in this issue

Links on this page

Archives of this issue

view archives of Antithrombotic Therapy for VTE Disease - ACCP VTE Therapy